Komipharm International Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 09:38 am
Share
Komipharm International Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 349.36 million compared to KRW 431.09 million a year ago. Net loss was KRW 726.45 million compared to net income of KRW 1,106.31 million a year ago. Basic loss per share from continuing operations was KRW 10 compared to basic earnings per share from continuing operations of KRW 15.4545 a year ago. Diluted loss per share from continuing operations was KRW 10 compared to diluted earnings per share from continuing operations of KRW 15.4545 a year ago. Basic loss per share was KRW 10 compared to basic earnings per share of KRW 15.4545 a year ago.
For the six months, sales was KRW 620.39 million compared to KRW 989.94 million a year ago. Net loss was KRW 1,553 million compared to net income of KRW 1,008.46 million a year ago. Basic loss per share from continuing operations was KRW 21.8182 compared to basic earnings per share from continuing operations of KRW 14.5455 a year ago. Diluted loss per share from continuing operations was KRW 21.8182 compared to diluted earnings per share from continuing operations of KRW 14.5455 a year ago. Basic loss per share was KRW 21.8182 compared to basic earnings per share of KRW 14.5455 a year ago.
Komipharm International Co Ltd is a Korea-based company principally engaged in the development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The Companyâs main products include veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle, vaccines for infectious bronchitis and Newcastle disease, and canine respiratory infection killed vaccines, and veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis, swine erysipelas, septicemia, leptospirosis and bacterial diseases for livestock. The Company also engages in research and development of anticancer drugs and cancer pain-relieving agents. In addition, the Company provides services such as pathological biopsies, serum tests, and bacteria tests.
KOMIPHARM INTERNATIONAL CO., LTD. 
